Zobrazeno 1 - 10
of 176
pro vyhledávání: '"D. T. Sleijfer"'
Autor:
P. A. Cook, Sally P. Stenning, R. de Wit, David P. Dearnaley, D. T. Sleijfer, S. B. Kaye, Richard Sylvester, Alan Horwich, Sophie D. Fossa, P.H.M. de Mulder, GM Mead, R. T.D. Oliver, Michael Cullen
Publikováno v:
Journal of Clinical Oncology, 15, 1844-1852
Journal of Clinical Oncology, 15, 5, pp. 1844-1852
Journal of Clinical Oncology, 15, 5, pp. 1844-1852
PURPOSE This prospective randomized multicenter trial was designed to evaluate the efficacy of carboplatin plus etoposide and bleomycin (CEB) versus cisplatin plus etoposide and bleomycin (BEP) in first-line chemotherapy of patients with good-risk no
Autor:
B, Biesma, P H, Willemse, N H, Mulder, D T, Sleijfer, J A, Gietema, R, Mull, P C, Limburg, J, Bouma, E, Vellenga, E G, de Vries
Publikováno v:
Blood. 80:1141-1148
To define the maximum tolerated dose and to study whether recombinant human interleukin-3 (rhIL-3) reduced chemotherapy-induced neutropenia and thrombocytopenia, 20 chemotherapy-naive patients with advanced ovarian cancer eligible for treatment with
Autor:
G, Jonker-Pool, H B, Van de Wiel, H J, Hoekstra, D T, Sleijfer, M F, Van Driel, J P, Van Basten, H S, Schraffordt Koops
Publikováno v:
Archives of sexual behavior. 30(1)
Literature concerning sexual functioning after treatment for testicular cancer from 1975-2000 is reviewed. After a literature search in Medline and Psylit was conducted, as well as a search for cross-references made, a meta-analysis was performed. To
Autor:
D J, Sonneveld, H J, Hoekstra, W T, van der Graaf, W J, Sluiter, N H, Mulder, P H, Willemse, H S, Koops, D T, Sleijfer
Publikováno v:
Cancer. 91(7)
The current study reviews chronologic changes in the long term outcome of patients with metastatic nonseminomatous testicular germ cell tumors (NSTGCT) who were treated at a single institution during the past two decades. The 10-year survival of prog
Autor:
C, Meijer, A, Timmer, E G, De Vries, J P, Groten, A, Knol, N, Zwart, W A, Dam, D T, Sleijfer, N H, Mulder
Publikováno v:
International journal of cancer. 85(6)
Cisplatin (CDDP) is an extremely active drug in the treatment of germ-cell tumours. Earlier, we found an unexpected inverse correlation between the total amount of sulfhydryl groups and CDDP sensitivity in a panel of 3 human germ-cell-tumour and 3 co
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 143(48)
Dyspnoea is a frequent symptom in advanced cancer patients. The control of breathing can be impaired by different mental and physical factors that may coincide and change over time. Apart from the treatment of specific pathophysiologic causes, sympto
Publikováno v:
Seminars in surgical oncology. 17(4)
Today, the standard treatment for patients with clinical Stage I non-seminomatous testicular germ cell tumors (NSTGCT) following orchidectomy is either primary retroperitoneal lymph node dissection (RPLND) or close surveillance with cisplatin-based p
Autor:
D J, Sonneveld, H J, Hoekstra, W T, Van Der Graaf, W J, Sluiter, H, Schraffordt Koops, D T, Sleijfer
Publikováno v:
BJU international. 84(1)
To determine the changes between 1977 and 1996 in the distribution of stages of testicular cancer (TC).The stage distribution was assessed, using various classifications, i.e. the Royal Marsden (RM), Indiana, European Organization for Research and Tr
Autor:
W E, de Graaff, J, van Echten, A Y, van der Veen, D T, Sleijfer, A, Timmer, H, Schraffordt Koops, B, de Jong
Publikováno v:
Cancer genetics and cytogenetics. 112(1)
The first published chromosomal pattern of the retroperitoneal lymph node metastasis of a malignant gonadal stroma cell tumor of the adult testis is presented. Karyotyping showed structural chromosomal abnormalities and loss of the Y-chromosome. This
Publikováno v:
Journal of cancer education : the official journal of the American Association for Cancer Education. 14(1)
Cancer patients may unnecessarily suffer from pain and other symptoms due to insufficient knowledge on the part of their doctors. In The Netherlands, the general practitioner is considered to be the key provider of palliative care for the cancer pati